Clinical Trial
-
Spine
Spinal Stabilization Technologies Ltd. Announces Start of LOPAIN 2 Clinical Trial in South America for Lumbar Degenerative Disc Disease
KILKENNY, Ireland, Nov. 16, 2022 /OrthoSpineNews/ — Spinal Stabilization Technologies (SST) has announced the start of the LOPAIN2 clinical trial of the PerQdisc™…
Read More » -
Spine
3Spine, Inc. Opens Innovative Clinical Trial for Spine Procedure with Steamboat Orthopaedic & Spine Institute in Colorado
Dr. J. Alex Sielatycki, SOSI Spine Surgeon; Jessica Nyquist, SOSI Physician Assistant; and Dr. Scott Hodges, 3Spine Medical Director performed…
Read More » -
Neuro
Mainstay Medical Announces Publication of Three-Year Patient Outcomes Data from ReActiv8-B Clinical Trial Demonstrating Long-Term Efficacy of ReActiv8® Restorative Neurostimulation™
Data continue to show compelling efficacy and safety, including improvement on all key measures of pain and disability, as compared…
Read More » -
Spine
AxioMed LLC Submits Final Module III to the FDA Becoming the First and Only Lumbar Viscoelastic Total Disc Replacement Company to Complete a USA IDE Clinical Trial
On August 8, 2022, AxioMed LLC submitted to the FDA all the required documents for Module III. This is the…
Read More » -
Sports Medicine
Ortho Regenerative Technologies Announces Enrollment of First Patient in its U.S. Phase l/ll Rotator Cuff Tear Repair Clinical Trial
First patient surgery completed; additional surgeries already scheduled8 clinical centres now fully initiated and recruiting / screening for patients MONTREAL, July…
Read More » -
Biologics
BioRestorative Therapies Announces First Patient Enrolled for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
First Patient Enrollment Milestone Completed MELVILLE, NY., June 30, 2022 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ:…
Read More » -
Spine
3Spine, Inc. Completes First US Surgeries
CHATTANOOGA, Tenn., June 29, 2022 /PRNewswire/ — 3Spine, Inc., a medical device company developing total joint replacement for the lumbar spine, today…
Read More » -
Spine
3Spine, Inc. Announces IDE Approval
CHATTANOOGA, Tenn., June 22, 2022 /PRNewswire/ — 3Spine, Inc., a medical device company developing total joint replacement for the lumbar spine, today…
Read More » -
Biologics
BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)
MELVILLE, NY., June 22, 2022 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage company focused…
Read More » -
Biologics
Ortho Regenerative Technologies Initiates Patients Recruitment For Its U.S. Phase I/II Rotator Cuff Tear Repair Clinical Trial
Contracting procedures completed for 6 of the 10 clinical trial sites5 sites fully activated, with ongoing patients’ screening and recruitment…
Read More » -
Spine
Clinical Trial to Test Replacement Devices for Two-Level Symptomatic Cervical Disc Disease
NEW YORK, June 1, 2022 /PRNewswire/ — A multicenter, prospective, randomized controlled trial is designed to assess the effectiveness of three different disc replacement…
Read More » -
Biologics
First Subjects Randomized and Dosed in the U.S. under Phase III Pivotal Trial for the Treatment of Pain Associated with Knee OA
Ongoing trial to assess the potential of Zilosul™ to address unmet medical need in OA which affects more than 72 million…
Read More » -
Spine
Spineart-100 U.S. Patients Treated In The Single Level IDE Clinical Trial Of BAGUERA®C Cervical Disc Prosthesis
LAGUNA HILLS, Calif., April 21, 2022 /PRNewswire/ — Spineart USA Inc. announced today that surgery has been performed on 100 patients in the single-level U.S.…
Read More » -
Spine
BioRestorative Therapies Announces Selection of 10 Clinical Sites for its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease
MELVILLE, N.Y.,, April 18, 2022 (GLOBE NEWSWIRE) — BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical stage…
Read More » -
Biologics
Ortho Regenerative Technologies Enters Into A Material Transfer Agreement With A Global Strategic Medical Company For Its Ortho-R Rotator Cuff Tear Repair Phase I/II U.S. Clinical Trial
MONTREAL, Feb. 7, 2022 /PRNewswire/ – Ortho Regenerative Technologies Inc. (CSE: ORTH) (OTC: ORTIF) (“Ortho” or the “Company“), a clinical-stage orthobiologics company focused on…
Read More »